Industry Insights: Advancing oligonucleotide therapeutics through regulatory approvals, clinical data, and AI-enabled discovery
Nucleic Acid Insights · 23.06.2026 · 3 (4) · 333–337
DOI: 10.18609/nai.2026.040 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acid Insights, online erschienen am 23.06.2026. Verfasst von Jokubas Leikauskas. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Across April and May 2026, the nucleic acid therapeutics field saw broad regulatory momentum, continued clinical advancement, and significant manufacturing investment. Regulatory highlights included MHRA authorisation of the ligand-conjugated ASO donidalorsen for hereditary angioedema prophylaxis and US FDA acceptance of GSK's NDA for the ASO bepirovirsen in chronic hepatitis B, the latter also receiving Breakthrough Therapy Designation. Clinical milestones featured the 50th patient treated under n-Lorem Foundation's personalized ASO programme and first results from HF-REVERT, the inaugural randomized trial of microRNA inhibition in heart failure. Manufacturing expansion featured prominently, with both Agilent Technologies and WuXi AppTec announcing major capacity increases for oligonucleotide production. AI-driven drug discovery also advanced, with RareLabs launching a robotics- and AI-enabled platform for rare disease ASO and siRNA development, and Ribo Life Science partnering with Insilico Medicine to integrate AI across its siRNA pipeline.
Zitieren
APA
Leikauskas, J. (2026). Industry Insights: Advancing oligonucleotide therapeutics through regulatory approvals, clinical data, and AI-enabled discovery. Nucleic Acid Insights, 3(4), 333–337. https://doi.org/10.18609/nai.2026.040
Vancouver
Leikauskas J. Industry Insights: Advancing oligonucleotide therapeutics through regulatory approvals, clinical data, and AI-enabled discovery. Nucleic Acid Insights. 2026;3(4):333–337. doi:10.18609/nai.2026.040
BibTeX
@article{Leikauskas2026,
author = {Leikauskas, Jokubas},
title = {Industry Insights: Advancing oligonucleotide therapeutics through regulatory approvals, clinical data, and AI-enabled discovery},
journal = {Nucleic Acid Insights},
year = {2026},
volume = {3},
number = {4},
pages = {333–337},
doi = {10.18609/nai.2026.040}
}
EUVIMED